Financing (Tables)

3 Months Ended

Apr. 03, 2020

Debt Disclosure [Abstract]

Components Of Debt

The components of the Company’s debt were as follows ($ in millions):

	April 3, 2020		December 31, 2019
Euro-denominated commercial paper (€4.3 billion and €4.6 billion, respectively)	$	4,616.0	$	5,146.2
U.S. dollar-denominated commercial paper	790.2		—
364-day revolving credit facility	—		—
Zero-coupon LYONs due 2021	33.2		33.6
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	276.7		275.8
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	863.8		894.8
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	270.1		279.8
2.05% senior notes due 2022 (the “2022 Biopharma Notes”)	697.3		696.9
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	554.7		558.9
1.7% senior notes due 2024 (€750.0 million aggregate principal amount) (the “2024 Euronotes”)	805.5		—
5-year revolving credit facility	2,500.0		—
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”)	696.2		696.2
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	862.6		893.7
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”)	497.4		497.3
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”)	1,343.6		1,392.3
2.1% senior notes due 2026 (€500.0 million aggregate principal amount) (the “2026 Euronotes”)	534.9		—
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	283.4		282.5
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	644.7		668.0
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”)	1,341.7		1,390.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	219.3		221.0
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”)	794.3		794.8
2.5% senior notes due 2030 (€500.0 million aggregate principal amount) (the “2030 Euronotes”)	535.3		—
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”)	1,880.8		1,948.7
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	489.3		487.8
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”)	1,335.1		1,383.6
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”)	888.9		890.3
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”)	499.4		499.4
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”)	801.7		830.9
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”)	888.4		890.2
Other	27.0		76.3
Total debt	25,971.5		21,729.1
Less: currently payable	3,234.3		212.4
Long-term debt	$	22,737.2	$	21,516.7

The following summarizes the key terms of the offerings in aggregate (€ in millions):

	Issue Date	Aggregate Principal Amount		Stated Annual Interest Rate		Issue Price (as % of Principal Amount)		Maturity Date	Interest Payment Dates (in arrears)
2024 Euronotes	March 30, 2020	€	750.0	1.700	%	99.931	%	March 30, 2024	March 30
2024 Euronotes	April 8, 2020	€	150.0	1.700	%	100.298	%	March 30, 2024	March 30
2026 Euronotes	March 30, 2020	€	500.0	2.100	%	99.717	%	September 30, 2026	September 30
2026 Euronotes	April 8, 2020	€	300.0	2.100	%	100.842	%	September 30, 2026	September 30
2030 Euronotes	March 30, 2020	€	500.0	2.500	%	99.642	%	March 30, 2030	March 30
2030 Euronotes	April 8, 2020	€	300.0	2.500	%	102.166	%	March 30, 2030	March 30

Key Terms of Euronotes Offering

The components of the Company’s debt were as follows ($ in millions):

	April 3, 2020		December 31, 2019
Euro-denominated commercial paper (€4.3 billion and €4.6 billion, respectively)	$	4,616.0	$	5,146.2
U.S. dollar-denominated commercial paper	790.2		—
364-day revolving credit facility	—		—
Zero-coupon LYONs due 2021	33.2		33.6
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	276.7		275.8
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	863.8		894.8
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	270.1		279.8
2.05% senior notes due 2022 (the “2022 Biopharma Notes”)	697.3		696.9
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	554.7		558.9
1.7% senior notes due 2024 (€750.0 million aggregate principal amount) (the “2024 Euronotes”)	805.5		—
5-year revolving credit facility	2,500.0		—
2.2% senior unsecured notes due 2024 (the “2024 Biopharma Notes”)	696.2		696.2
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	862.6		893.7
3.35% senior unsecured notes due 2025 (the “2025 U.S. Notes”)	497.4		497.3
0.2% senior unsecured notes due 2026 (€1.3 billion aggregate principal amount) (the “2026 Biopharma Euronotes”)	1,343.6		1,392.3
2.1% senior notes due 2026 (€500.0 million aggregate principal amount) (the “2026 Euronotes”)	534.9		—
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	283.4		282.5
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	644.7		668.0
0.45% senior unsecured notes due 2028 (€1.3 billion aggregate principal amount) (the “2028 Biopharma Euronotes”)	1,341.7		1,390.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	219.3		221.0
2.6% senior unsecured notes due 2029 (the “2029 Biopharma Notes”)	794.3		794.8
2.5% senior notes due 2030 (€500.0 million aggregate principal amount) (the “2030 Euronotes”)	535.3		—
0.75% senior unsecured notes due 2031 (€1.8 billion aggregate principal amount) (the “2031 Biopharma Euronotes”)	1,880.8		1,948.7
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	489.3		487.8
1.35% senior unsecured notes due 2039 (€1.3 billion aggregate principal amount) (the “2039 Biopharma Euronotes”)	1,335.1		1,383.6
3.25% senior unsecured notes due 2029 (the “2039 Biopharma Notes”)	888.9		890.3
4.375% senior unsecured notes due 2045 (the “2045 U.S. Notes”)	499.4		499.4
1.8% senior unsecured notes due 2049 (€750.0 million aggregate principal amount) (the “2049 Biopharma Euronotes”)	801.7		830.9
3.4% senior unsecured notes due 2049 (the “2049 Biopharma Notes”)	888.4		890.2
Other	27.0		76.3
Total debt	25,971.5		21,729.1
Less: currently payable	3,234.3		212.4
Long-term debt	$	22,737.2	$	21,516.7

The following summarizes the key terms of the offerings in aggregate (€ in millions):

	Issue Date	Aggregate Principal Amount		Stated Annual Interest Rate		Issue Price (as % of Principal Amount)		Maturity Date	Interest Payment Dates (in arrears)
2024 Euronotes	March 30, 2020	€	750.0	1.700	%	99.931	%	March 30, 2024	March 30
2024 Euronotes	April 8, 2020	€	150.0	1.700	%	100.298	%	March 30, 2024	March 30
2026 Euronotes	March 30, 2020	€	500.0	2.100	%	99.717	%	September 30, 2026	September 30
2026 Euronotes	April 8, 2020	€	300.0	2.100	%	100.842	%	September 30, 2026	September 30
2030 Euronotes	March 30, 2020	€	500.0	2.500	%	99.642	%	March 30, 2030	March 30
2030 Euronotes	April 8, 2020	€	300.0	2.500	%	102.166	%	March 30, 2030	March 30